Breaking News Instant updates and real-time market news.

NKTR

Nektar

$22.11

6.61 (42.65%)

05:54
03/21/17
03/21
05:54
03/21/17
05:54

Nektar price target raised to $24 from $18 at JPMorgan

JPMorgan analyst Jessica Fye raised her price target for Nektar Therapeutics to $24 citing the positive phase III results for NKTR-181 in pain. The analyst sees a "strong probability" that Nektar partners the drug through the rest of phase III development and to commercialization. She keeps an Overweight rating on the shares.

  • 29

    Mar

  • 01

    Apr

NKTR Nektar
$22.11

6.61 (42.65%)

03/21/17
JEFF
03/21/17
NO CHANGE
Target $25
JEFF
Buy
Nektar price target raised to $25 from $17 at Jefferies
Jefferies analyst David Steinberg raised his price target for Nektar Therapeutics to $25 citing the "unexpected" Phase 3 success for NKTR-181. In a research note tiled "NKTR-181 Back From the Dead; Could Become a Major Product in Chronic Pain," Steinberg says the drug could become the company's largest and most profitable product since it directly addresses the "opioid epidemic." NKTR-181 could bring "significant value" to Nektar as early as 2020, the analyst contends. Steinberg adds that the company now fits his takeover thesis. He keeps a Buy rating on the shares.
03/20/17
ROTH
03/20/17
NO CHANGE
Target $31
ROTH
Buy
Roth Capital raises Nektar price target to $31 after 'impressive' opioid data
Roth Capital analyst Michael Higgins called Nektar's Phase 3 results for NKTR-181 "impressive" and said he expect management will now enter into negotiations to out-license the drug while meeting with the FDA. Higgins, who believes the drug is worth $2B by "conservatively" estimating its value at 3-4X peak sales, raised his price target on Nektar shares to $31 from $23 and reiterates a Buy rating on the stock.
03/20/17
PIPR
03/20/17
NO CHANGE
Target $29
PIPR
Overweight
Nektar price target raised to $29 after opioid trial success at Piper Jaffray
Piper Jaffray analyst Joshua Schimmer said he thought prospects of success for NKTR-181 were very low after a failed Phase 2 study but he was "happy to be proven wrong" after the SUMMIT trial succeeded. A human abuse liability study will read-out around mid-2017, after which the company will meet with the FDA to discuss whether the package for NKTR-181 is adequate for filing, Schimmer noted. He raised his price target on Nektar shares to $29 from $25 and keeps an Overweight rating on the stock, which he calls his "top mid-cap biotech stocks for other reasons," such as its multiple royalty streams from partnered products and its emerging immuno-oncology platform.
01/26/17
PIPR
01/26/17
NO CHANGE
PIPR
Overweight
Celgene acquisition highlights underappreciated Nektar asset, says Piper Jaffray
After Celgene (CELG) announced this morning a deal to acquire Delinia for $300M plus up to $475M in potential milestones, Piper Jaffray analyst Joshua Schimmer noted that the company's lead asset, DEL106, being developed for autoimmune disorders, is similar to Nektar's (NKTR) NKTR-358. While many investors are familiar with Nektar's immune-oncology program, NKTR-214, far fewer are familiar with NKTR-358, though both represent potential blockbuster opportunities if successful, Schimmer tells investors. He keeps an Overweight rating on Nektar, which he identifies as one of his top mid-cap picks.

TODAY'S FREE FLY STORIES

06:05
05/29/17
05/29
06:05
05/29/17
06:05
General news
WTI crude futures are off by 0.2% »

WTI crude futures are off…

03:10
05/29/17
05/29
03:10
05/29/17
03:10
General news
FX Update: The dollar majors have been plying narrow ranges »

FX Update: The dollar…

03:05
05/29/17
05/29
03:05
05/29/17
03:05
General news
Fed's Williams: three hikes this year still make sense. »

Fed's Williams:…

RBGLY

Reckitt Benckiser

$20.53

0.04 (0.20%)

, MJN

Mead Johnson

$89.29

0.1 (0.11%)

15:32
05/28/17
05/28
15:32
05/28/17
15:32
Conference/Events
Mead Johnson to host special shareholder meeting »

Special Shareholder…

RBGLY

Reckitt Benckiser

$20.53

0.04 (0.20%)

MJN

Mead Johnson

$89.29

0.1 (0.11%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    May

PHH

PHH Corp.

$13.58

0.06 (0.44%)

15:25
05/28/17
05/28
15:25
05/28/17
15:25
Conference/Events
PHH Corp. to host special shareholder meeting »

Special Shareholder…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    May

TPIV

TapImmune

$3.71

-0.03 (-0.80%)

14:37
05/28/17
05/28
14:37
05/28/17
14:37
Conference/Events
TapImmune to hold a business update conference call »

Management holds a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    May

SCOR

comScore

$24.80

-0.15 (-0.60%)

14:35
05/28/17
05/28
14:35
05/28/17
14:35
Conference/Events
comScore to host business news update conference call »

Management holds a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    May

BMY

Bristol-Myers

$53.97

-0.42 (-0.77%)

14:12
05/28/17
05/28
14:12
05/28/17
14:12
Conference/Events
Bristol-Myers to hold a pharmaceutical update conference call »

Management provides an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Jun

  • 04

    Jun

  • 06

    Jun

  • 24

    Sep

LOXO

Loxo Oncology

$47.44

-0.06 (-0.13%)

14:10
05/28/17
05/28
14:10
05/28/17
14:10
Conference/Events
Loxo Oncology to hold a pharmaceutical update conference call »

Management discusses the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Jun

  • 04

    Jun

  • 06

    Jun

ADRO

Aduro Biotech

$10.05

-0.15 (-1.47%)

14:07
05/28/17
05/28
14:07
05/28/17
14:07
Conference/Events
Aduro Biotech to host analyst and investor meeting »

Management hosts special…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Jun

ELGX

Endologix

$4.73

-0.05 (-1.05%)

14:06
05/28/17
05/28
14:06
05/28/17
14:06
Conference/Events
Endologix to hold a pharmaceutical update conference call »

Management discusses the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    May

  • 31

    May

  • 03

    Jun

TSRO

Tesaro

$149.11

-4.08 (-2.66%)

14:02
05/28/17
05/28
14:02
05/28/17
14:02
Conference/Events
Tesaro to hold an analyst and investor briefing »

Management hosts an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Jun

  • 03

    Jun

  • 30

    Jun

ICE

IntercontinentalExchange

$60.35

-0.09 (-0.15%)

13:57
05/28/17
05/28
13:57
05/28/17
13:57
Conference/Events
IntercontinentalExchange to host investor day »

Investor Day to be held…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Jun

  • 07

    Jun

CPA

Copa Holdings

$111.69

0.2 (0.18%)

13:48
05/28/17
05/28
13:48
05/28/17
13:48
Conference/Events
Copa Holdings to host investor day »

Investor Day to be held…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Jun

CAH

Cardinal Health

$73.10

-0.34 (-0.46%)

13:31
05/28/17
05/28
13:31
05/28/17
13:31
Conference/Events
Cardinal Health to hold a meeting »

Dublin Day to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Jun

BPMX

BioPharmX

$0.64

0.0089 (1.41%)

13:26
05/28/17
05/28
13:26
05/28/17
13:26
Conference/Events
BioPharmX holds state of acne symposium »

Management provides…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NVS

Novartis

$80.63

-0.72 (-0.89%)

13:20
05/28/17
05/28
13:20
05/28/17
13:20
Conference/Events
Novartis to hold a meeting »

Meet the Management Day…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Jun

  • 26

    Jun

CNC

Centene

$74.57

-0.68 (-0.90%)

, MOH

Molina Healthcare

$66.87

-0.21 (-0.31%)

12:34
05/27/17
05/27
12:34
05/27/17
12:34
Hot Stocks
Week in review: How Trump's policies moved stocks »

Catch up on the top…

CNC

Centene

$74.57

-0.68 (-0.90%)

MOH

Molina Healthcare

$66.87

-0.21 (-0.31%)

HUM

Humana

$232.25

0.02 (0.01%)

AET

Aetna

$145.57

0.34 (0.23%)

ANTM

Anthem

$183.08

1.58 (0.87%)

UNH

UnitedHealth

$177.50

-0.55 (-0.31%)

WCG

WellCare

$172.97

0.15 (0.09%)

CI

Cigna

$161.32

-0.33 (-0.20%)

BX

Blackstone

$32.58

0.11 (0.34%)

NUE

Nucor

$58.15

-0.22 (-0.38%)

X

U.S. Steel

$19.74

-0.51 (-2.52%)

STLD

Steel Dynamics

$33.71

-0.73 (-2.12%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    May

  • 13

    Jun

  • 16

    Jun

21:00
05/26/17
05/26
21:00
05/26/17
21:00
General news
Breaking General news story  »

San Francisco Federal…

20:00
05/26/17
05/26
20:00
05/26/17
20:00
General news
Breaking General news story  »

San Francisco Federal…

JUNO

Juno Therapeutics

$23.30

-2.22 (-8.70%)

18:11
05/26/17
05/26
18:11
05/26/17
18:11
Hot Stocks
Juno Therapeutics director acquires 20,000 common shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Jun

UNH

UnitedHealth

$177.50

-0.55 (-0.31%)

18:06
05/26/17
05/26
18:06
05/26/17
18:06
Hot Stocks
UnitedHealth's OptumHealth awarded $200.5M government contract »

UnitedHealth's…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    May

VEC

Vectrus

$29.62

0.02 (0.07%)

17:56
05/26/17
05/26
17:56
05/26/17
17:56
Hot Stocks
Vectrus Systems awarded $212.03M modification to government contract »

Vectrus Systems was…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IMMY

Imprimis

$3.34

-0.06 (-1.76%)

17:52
05/26/17
05/26
17:52
05/26/17
17:52
Syndicate
Breaking Syndicate news story on Imprimis »

Imprimis files $75M mixed…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IRCP

IRSA Propiedades Comerciales

$43.58

-0.33 (-0.75%)

17:51
05/26/17
05/26
17:51
05/26/17
17:51
Syndicate
Breaking Syndicate news story on IRSA Propiedades Comerciales »

IRSA Propiedades…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.